OncMadness: Round 2, Survivorship 16

The second round of voting in OncMadness 2020 is over. Let’s check out where things stand and see if you’re on track to match the Blue Ribbon Panel’s choices.

Survivorship 16

Region: Chemotherapy

TAILORx in early breast cancer versus Gentler therapy for geriatric patients

And the winner is: TAILORx

Here’s what our Blue Ribbon Panel had to say:

“Precision treatment.”

“Want to focus on improving precision science.”

Region: Supportive Care

Constipation treatment versus Co-analgesics for cancer pain

And the winner is: Co-analgesics for cancer pain

Here’s what our Blue Ribbon Panel had to say:

“Important for avoiding opioid dependence.”

“Opioid utilization.”

“Community interest.”

Region: Immune and Cellular Tx

Checkpoint inhibition in metastatic NSCLC versus CAR-T in hematologic malignancies

And the winner is: Checkpoint inhibition in metastatic NSCLC

Here’s what our Blue Ribbon Panel had to say:

“Larger population with larger impact thus far.”

“Changed standard of care.”

Region: Patient-Reported Outcomes

Real-world data and evidence versus Care fragmentation

And the winner is: Real-world data and evidence

Here’s what our Blue Ribbon Panel had to say:

“Important to understand strengths and limitations.”

“Long-term solution.”

Region: Health Policy

Use of clinical pathways versus Price of new therapies

And the winner is: Use of clinical pathways

Here’s what our Blue Ribbon Panel had to say:

“Important issue.”

“Consistent treatment needed.”

Region: Precision Therapy and Targeted Agents

BEACON and RAS targeting in colorectal cancer versus CDK4/6 inhibitors in metastatic breast cancer

And the winner is: BEACON and RAS targeting in colorectal cancer

Here’s what our Blue Ribbon Panel had to say:

“Transforming CRC.”

“Unmet need.”

Region: Local Therapy

Local approaches for oligometastatic disease versus De-escalation in HPV-positive oropharyngeal cancers

And the winner is: De-escalation in HPV-positive oropharyngeal cancers

Here’s what our Blue Ribbon Panel had to say:

“The next step in what to do when therapy is curative.”

“Major QoL implications.”

Region: Screening and Risk Reduction

Colorectal cancer screening versus Early detection

And the winner is: Early detection

Here’s what our Blue Ribbon Panel had to say:

“Molecular testing and circulating DNA is the future.”

“Important to continue to explore biomarkers as non-invasive screening tools.”

Last Updated May 28, 2020